The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Should we treat newly diagnosed patients with CLL differently after ASH 2019?

Dec 12, 2019

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub was pleased to speak to Astrid Pavlovsky, Fundaleu CHP, Buenos Aires, AR. We asked: Should we treat newly diagnosed patients with chronic lymphocytic leukemia differently after ASH 2019?

Astrid Pavlovsky talks about the importance of genetic characterization of CLL to guide patient treatment pathway. She also discusses the results of the ELEVATE trial, that examines a new treatment option for elderly patients with CLL.

Should we treat newly diagnosed patients with CLL differently after ASH 2019?

[[button1]]